News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Bereaved parents visit ICR lab supported in daughter’s memory
The parents of Kelly Turner, Linda and Martin, recently visited The Institute of Cancer Research, London, to see the labs doing research into the cancer that took Kelly’s life.
Scientists talk medicine and engineering with potential partners at the Harwell campus
The ICR's Enterprise Unit has hosted a networking event alongside the Science and Technology Facilities Council (STFC) at Harwell, a science and technology campus near Oxford.
"Without research there will be no cure" – why parents fund vital research into children’s cancer
ICR researchers are working hard to improve children’s cancer treatment. This children’s cancer awareness month, our parent-led charity supporters – who fund so much of this crucial work – have shared their inspirational stories with us and explain why they choose to work with the ICR.
Professor to cycle 60 miles to give back to the Newcastle charity supporting her research into childhood cancer
A scientist who studies a rare form of childhood cancer is joining a 60 mile cycle ride through Northumberland in support of the charity which has funded her research for more than ten years.
.jpg?sfvrsn=d3b6f9c1_2 "White blood cells (leukocytes)")
First-degree relatives of blood cancer patients at increased risk, major new study reveals
People with a parent, sibling or child affected by blood cancer are more likely to be diagnosed with the disease, a new study has shown.
Poet Laureate’s ‘poem on a pill’ cuts cancer down to size
Newly appointed Poet Laureate Simon Armitage has written a poem for The Institute of Cancer Research, London, symbolising the goal of precision science to turn cancer into a manageable disease.
Positive clinical trial results for olaparib in advanced prostate cancer
The preliminary results of a major phase III clinical trial show that the genetically targeted drug olaparib improves outcomes for men with advanced prostate cancer whose tumours have DNA repair faults.
Artificial intelligence reveals new breast cancer types that respond differently to treatment
Scientists have used artificial intelligence to recognise patterns in breast cancer – and uncovered five new types of the disease, each matched to different personalised treatments.
Personalised ‘liquid biopsy’ could detect return of breast cancer nearly eleven months earlier than hospital scans
Multicentre UK study finds new blood test could detect the return and spread of breast cancer on average 10.7 months before tumours became visible on scans or patients developed symptoms
Tumour-liquifying microbubbles and immune cell tracking: UK’s first convergence science centre officially launches
Two of the UK’s foremost academic research institutions, The Institute of Cancer Research, London, and Imperial College London, are coming together with funding from Cancer Research UK to launch the new £13 million Convergence Science Centre.
ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations
The ICR responds to the approval by NHS regulators NICE for the use of targeted cancer drug olaparib earlier in the course of treatment for women with late-stage ovarian cancer and other gynaecological cancers who have BRCA gene mutations.
Gene test picks out prostate cancers patients who could benefit from ‘search-and-destroy’ medicine
Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.
